ATRA
Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.96
−2.40%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.26
From 52W high−50.47%
Volume12450.00
Market cap$89.94M
P/E (TTM)—
P/S (TTM)14.5x
Div yield—
Key dataOct 19, 2026
Open
$9.26
From 52W high
−50.47%
Volume
12450.00
Market cap
$89.94M
ValuationView details →
P/E (Fwd)
11.5x
EV/EBITDA
−6.6x
P/E (TTM)
—
RSI (14)
49.0
MomentumView details →
1D Return
−2.40%
YTD Return
−49.31%
SummaryUpdated Jun 1, 2026
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a clinical-stage biotechnology company founded in 2012 and headquartered in South San Francisco, California. The company went public in October 2014 and specializes in developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. Atara has evolved from a broad-based immunotherapy developer to a more focused organization following strategic partnerships and operational restructuring in recent years.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration accepted Pierre Fabre Pharmaceuticals’ resubmitted Biologics License Application for tabelecleucel.6d agoPierre Fabre Pharmaceuticals resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration, as reported by partner Atara Biotherapeutics.20d agoAtara Biotherapeutics appointed Brian Cherry as a Class I director and elected AnhCo Nguyen and Nachi Subramanian as directors, effective June 2026.130d ago